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The good news from studies of Ebola survivors is that immunity against the virus appears to be long-lasting, sometimes even lifelong. The fi rst documented epidemic in the Democratic Republic of the Congo (then known as Zaire) left only 38 survivors. Eleven years after the event, some of them were tested and found to still have an effi cient immune response against the virus. A recent study re-examined six survivors that had suffered a serologically confi rmed Ebola infection in 1976 as well as eight others who had had the characteristic symptoms but no defi nitive confi rmation. Using three independent measures of immune responsiveness to Ebola, Anne Rimoin from the University of California at Los Angeles, USA, and colleagues found that sera from some of the survivors still responded positively to all three challenges, and were still fully able to neutralise live viruses (J. Infect. Dis. (2017) DOI: https://doi.org/10.1093/infdis/jix584).
This fi nding confi rms the value of the blood transfusion treatment that has been used in some cases during the recent epidemic. It also raises hopes that immunological treatment options could be developed on the basis of the long-term immunity observed in survivors.
All in all, many valuable lessons have been learned from the recent epidemic, ranging from the challenges of quarantine procedures and effi cient healthcare provision in such a crisis, through to the value of ring vaccinations and other preventive measures. Education and awareness efforts have also been stepped up as knowledge of transmission routes is crucial for the success of quarantine measures.
To better avoid further surprise epidemics of zoonotic diseases, however, much better understanding of the disease mechanisms and their ecological background in wildlife will be necessary. Research is only beginning to answer these important questions, and the problem is that we don't know how much time we have until the next epidemic strikes.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk When I arrived in London in 1968, I was 30 years old. I had done no laboratory science and I knew almost no immunology. NIMR was buzzing with outstanding immunologists, making it a perfect place to learn. Av suggested that I test whether an antigen on the surface of mouse thymocytes called theta (now called Thy1) could serve as a marker for peripheral T lymphocytes in mice. I showed that it could, which then allowed me and my colleagues to show that surface immunoglobulin could serve as a marker for B lymphocytes. Armed with these cell-surface markers, we were able to study the properties, functions, and development of both classes of mouse lymphocytes. Because Av declined to put his name on any of my papers, I became a well-known immunologist in my fi rst two years in science. When Av accepted a professorship at UCL in 1971, he invited me to move with him. Until that moment, I considered myself a clinical neurologist, but I quickly realised I should give up medicine, stay in the UK, and become a full-time scientist.
Martin Raff
Do you think there is a cultural difference between working as a scientist in the UK compared with the US? Having only worked in science in the UK, I am not well placed to answer that. My impression, however, is that -in my day, at least -curiosity was the main driver of scientifi c discovery in Britain, whereas in the US competition seemed to have a bigger role: American scientists appeared to spend more time looking over their shoulder at their competitors than did British scientists. Science everywhere, however, is becoming more competitive, but I suspect that these differences persist even today. When you [Jordan] were a postdoc at UCSF, you commented that the American postdocs often worked nights and weekends, whereas you rarely did.
Current Biology 28, R51-R65, January 22, 2018 R55 Would you encourage your grandchildren to become scientists today? I don't think I encouraged or discouraged you [Jordan] from becoming a scientist. I assumed that you could see that I loved doing science and had a very good life doing it. But, being a scientist then was very much easier than it is now: it was easier to get your papers published, to get grants, and to get a job. There is also a lot more bureaucracy to deal with today, leaving much less time for thinking about science. There is also increasing pressure from funding bodies to make biomedical science relevant to disease, which is fair enough, but it risks decreasing curiosity-based basic research and the fun of trying to fi gure out how the world works.
So, although I might not actively encourage my grandchildren to become professional scientists, I might encourage them to do a science degree and even a Ph.D. It is becoming increasingly important to have a scientifi cally literate population, so the more scientifi cally trained citizens the better. A scientifi c education might help you distinguish real news from fake news. Sadly, across the world, we are moving in the opposite direction, which puts us all in danger.
Is there anything that realistically can be done to make science a more attractive career? I am not sure that is what is needed. In the UK, US, and many other countries, we are already training too many biomedical scientists, as evidenced by the failure of most biomedical postdocs to fi nd appropriate jobs. We need to make sure that those who start along these oversubscribed pathways know what their chances are of fi nding appropriate work and that we make sure their training also helps equip them for other careers.
I do think it's important to persuade governments and funding bodies to preserve vigorous, curiosity-driven basic research. There is abundant evidence for the success and importance of this type of research for the wellbeing of a country's citizens and for the competitiveness of its industries. There is not much point in scientists arguing the case, however, as they would be seen as just another self-interested profession. Big pharmaceutical and biotech companies could play a much bigger part here, as they know that they would have little future without academic basic research, and politicians and administrators are more likely to listen to them. I do worry about the trend to push basic scientists to take on more translational projects that are better done by industry.
You're a co-author of the very successful textbook Molecular Biology of the Cell, now in its 6 th edition. How has that affected you and your career? It has been very important to me. First, I learned an enormous amount of basic science from my co-authors, and it has helped broaden my scientifi c perspective and interests. Second, it improved my writing, as each chapter gets rewritten many times, with drafts getting passed around between the authors and then edited by a developmental editor and a copy editor, and undergraduate students are often asked to comment on the clarity of the writing. Third, the royalties from the book eliminated any fi nancial worries.
When Jim Watson initially recruited the original authors of the book, he argued that it doesn't matter what you do in your research -if it's important, somebody else will do it eventually. But, if we get this right and produce a textbook that successfully integrates molecular and cell biology, it would be hugely infl uential, and it would probably be the most important contribution to science we would make. In my case at least, I think he was right.
Everyone knows the book as 'Alberts'. I know you're going to say it doesn't bother you, but don't you secretly wish your last name was Aardvark? No. By a happy coincidence, it is entirely appropriate that it's called 'Alberts' because Bruce Alberts is undoubtedly the most important of the co-authors and is still the main intellectual driving force behind the book.
You were on the Lasker Jury for many years. Do you think that prizes are good for science? I think they are both good and bad. They are good because they provide excellent publicity for science by periodically shining a light on great science and scientists, so the public get to see what and whom it has been supporting Jordan and Martin Raff.
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Current Biology 28, R51-R65, January 22, 2018 © 2017 Elsevier Ltd. so generously for so long. They are bad partly because they can be unfair. Many of the biggest prizes -including the Nobel and Lasker Prizes -limit the number of winners to three each year in any one scientifi c area; in some cases, it's not possible to pick three winners without omitting equally worthy candidates, so either the award is unfair or some areas are unjustly by-passed. There is also an inevitable downside to each prize announcement every year because many more potential candidates are disappointed than are rewarded.
I do think the huge amount of money awarded with the big prizes makes little sense, as the winners don't need it, and they often win multiple prizes. One of the nice things about being a scientist is that your success is generally judged by your discoveries rather than the amount of money you make. The prestige of a science prize should not depend on its cash value. It would be better to reduce the prize money and use the savings to support young scientists.
Is scientifi c fraud a big problem, and, if so, what can be done to fi x it? There is no doubt that fraud is very destructive to science. I think it is much more common than scientists generally believe or admit. That's because individuals and institutions almost always hide fraud when it occurs. When it is uncovered in a laboratory, it's usually not in the interest of the group leader, the innocent lab members, the institution, or science in general for the fraud to become widely known, as the reputation of all of them would suffer. This is why the default response is to sweep the fraud under the carpet, which is bad for science, and is why it is more common than the science community acknowledges.
What can be done about it? Fraud is often fi rst reported by a whistleblower, who usually gets squished like a bug. We need better ways to protect them and to acknowledge their courage and their importance to science. Institutions need to have clear rules and pathways for dealing with suspected fraud and to be more transparent in their investigations. Investigating committees should include lawyers to ensure due process and to avoid lawsuits. The scientifi c community needs to acknowledge that fraud is an important problem and discuss it more widely and more openly.
You closed your lab when you were about to turn 65. A compulsory retirement age in science is a hot topic at the moment. Do you have any regrets or thoughts? I have no regrets at all. I loved doing science and I love my retirement. When I was about 50 years old, I learned that Michael Heldelberger, an eminent immunochemist at Columbia University, still had an NIH grant when he was 101. I realised that, if I followed his example, I was less than a third of the way through my scientifi c career, which I found acutely depressing. I promised myself then and there that I would retire by 65, and I immediately cheered up. I still have an offi ce at UCL, serve on some scientifi c advisory boards, and am involved in book writing. The main difference is that I no longer have to worry about my students and postdocs -their experiments, papers, mental state, and future; it was only after retirement that I realised how much I worried about these things.
Another great thing about retirement is that I get to read things I didn't have time to read before, such as the New York Review of Books. Also, it is well known that contentment tends to increase with retirement, at least partly because expectation -the denominator in measuring contentment -decreases with age. For all these reasons, I am a strong advocate for retirement, fully realising that my enthusiasm has depended on not having fi nancial worries and being relatively healthy. As has been true for my entire life, all of this has depended on a remarkable amount of good luck.
